Search | IOVS | ARVO Journals

Showing 1 – 20 of 32

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Clinical characteristics of pediatric patients with ocular inflammation over five years in western Tokyo

Mutsuhiro Tauchi; Yusuke Nishio; Junko Hori

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5060.

ARVO Annual Meeting Abstract June 2024

Epidemiologic study of intraocular inflammation patients for 5 years at a tertiary center in western Tokyo.

Ryota Suga; Toshiki Kawahara; Sayaka Haku; Mutsuhiro Tauchi; Eri Suzuki; Yusuke Nishio; Yuichiro Nakano; Junko Hori

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5047.

ARVO Annual Meeting Abstract June 2020

A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease

Takashi Ono; Manabu Mochizuki; Hiroshi Goto; Tsutomu Sakai; Fumihiko Nitta; Nobuhisa Mizuki; Hiroshi Takase; Yutaka Kaneko; Junko Hori; Satoko Nakano; Nobuhisa Nao-i; Nobuyuki Ohguro

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3169.

Immunology and Microbiology December 2019

VISTA Is Crucial for Corneal Allograft Survival and Maintenance of Immune Privilege

PDF

Tomoyuki Kunishige; Hiroko Taniguchi; Tatsukuni Ohno; Miyuki Azuma; Junko Hori
TAGS: allografting, cornea, immune privilege, monoclonal antibodies, t-lymphocytes, mice, immunoglobulin g, eye
Invest. Ophthalmol. Vis. Sci.. 2019; 60(15):4958-4965. https://doi.org/10.1167/iovs.19-27322

Includes: Supplemental Content

ARVO Annual Meeting Abstract July 2019

Clinical course and treatment of prolonged cases in Vogt-Koyanagi-Harada disease.

Ayaka Takeda; Naka Shiratori; Satoko Yui; Junko Hori

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3504.

ARVO Annual Meeting Abstract July 2018

A retrospective study for scleritis therapy with immunosupressant and biological agents

Noriko Oishi; Satoko Yui; Naka Shiratori; Junko Hori

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):425.

ARVO Annual Meeting Abstract July 2018

Expression of T cell/transmembrane, immunoglobulin, and mucin (TIM)-4 in normal cornea and corneal grafts

Ayaka Takeda; Hiroko Taniguchi; Tomoyuki Kunishige; Hisaya Akiba; Hideo Yagita; Junko Hori

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):510.

ARVO Annual Meeting Abstract June 2017

Clinical statistics for secondary glaucoma in patients with scleritis

Tomoyuki Kunishige; Kohei Miyata; Satoko Yui; Kenji Nakamoto; Junko Hori

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):552.

ARVO Annual Meeting Abstract June 2017

Role of B7-H3/TLT-2 pathway in immune privilege of corneal allografts

Hiroko Taniguchi; Hidenori Hase; Hisaya Akiba; Hideo Yagita; Miyuki Azuma; Junko Hori

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5734.

Cornea January 2017

Immune Cells on the Corneal Endothelium of an Allogeneic Corneal Transplantation Rabbit Model

PDF

Elena Koudouna; Naoki Okumura; Yugo Okazaki; Shinichiro Nakano; Ryota Inoue; Nigel J. Fullwood; Junko Hori; Shigeru Kinoshita; Noriko Koizumi
TAGS: corneal endothelium, keratoplasty, oryctolagus cuniculus, descemet stripping endothelial keratoplasty, tissue transplants, cornea, endothelium
Invest. Ophthalmol. Vis. Sci.. 2017; 58(1):242-251. https://doi.org/10.1167/iovs.16-20019

Immunology and Microbiology December 2016

Protective Role of ICOS and ICOS Ligand in Corneal Transplantation and in Maintenance of Immune Privilege

PDF

Tomoyuki Kunishige; Hiroko Taniguchi; Misao Terada; Hisaya Akiba; Hideo Yagita; Ryo Abe; Junko Hori
TAGS: allografting, cornea, keratoplasty, ligands, mice, polymerase chain reaction, t-lymphocytes
Invest. Ophthalmol. Vis. Sci.. 2016; 57(15):6815-6823. https://doi.org/10.1167/iovs.16-20644

ARVO Annual Meeting Abstract September 2016

Expression of ICOS and Foxp3 on T cells infiltrating in corneal allografts

Hiroko Taniguchi; Tomoyuki Kunishige; Hisaya Akiba; Hideo Yagita; Ryo Abe; Junko Hori

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):318.

ARVO Annual Meeting Abstract September 2016

Role of V-domain Ig suppressor of T cell activation (VISTA) in Anterior Chamber Associated Immune Deviation

Tomoyuki Kunishige; Hiroko Taniguchi; Tatsukuni Ohno; MIyuki Azuma; Junko Hori

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):319.

ARVO Annual Meeting Abstract September 2016

Clinical statistics for recurrence of Vogt-Koyanagi-Harada disease

Naka Shiratori; Tomoyuki Kunishige; Junko Hori

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):1870.

ARVO Annual Meeting Abstract June 2015

Long-term Ocular Analysis in Murine Model of Anterior Scleritis

Hiroko Taniguchi; Yuki Kitahara; Junko Hori

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):858.

ARVO Annual Meeting Abstract June 2015

Mechanisms of V-domain Ig suppressor of T cell activation (VISTA)-mediated acceptance of corneal allografts

Tomoyuki Kunishige; Hiroko Taniguchi; Tatsukuni Ohno; Miyuki Azuma; Junko Hori

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):4872.

ARVO Annual Meeting Abstract June 2013

V-domain Ig Suppressor of T Cell Activation (VISTA) is Necessary for Corneal Allograft Survival

Tomoyuki Kunishige; Hiroko Taniguchi; Tatsukuni Ohno; Miyuki Azuma; Junko Hori

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):2032.

ARVO Annual Meeting Abstract June 2013

Incidence of Endogenous Intraocular Inflammation in the Central Tokyo of Japan for 8 Years from 2004 to 2012

Motoko Serizawa; Yukiko Ito; Reiko Tsukada; Hiroshi Takahashi; Hiroko Taniguchi; Junko Hori

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):2526.

ARVO Annual Meeting Abstract June 2013

Induction of Corneal Inflammation in the Collagen-Induced Scleritis Model

Hiroko Taniguchi; Yuki Kitahara; Junko Hori

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):2532.

ARVO Annual Meeting Abstract March 2012

Clinical Features and Treatment Outcome of Japanese Patients with Scleritis

Kazuhisa Takahashi; Kuniko Wakayama; Hiroshi Takahashi; Junko Hori

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):1255.

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Clinical characteristics of pediatric patients with ocular inflammation over five years in western Tokyo

Epidemiologic study of intraocular inflammation patients for 5 years at a tertiary center in western Tokyo.

A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease

VISTA Is Crucial for Corneal Allograft Survival and Maintenance of Immune Privilege

Clinical course and treatment of prolonged cases in Vogt-Koyanagi-Harada disease.

A retrospective study for scleritis therapy with immunosupressant and biological agents

Expression of T cell/transmembrane, immunoglobulin, and mucin (TIM)-4 in normal cornea and corneal grafts

Clinical statistics for secondary glaucoma in patients with scleritis

Role of B7-H3/TLT-2 pathway in immune privilege of corneal allografts

Immune Cells on the Corneal Endothelium of an Allogeneic Corneal Transplantation Rabbit Model

Protective Role of ICOS and ICOS Ligand in Corneal Transplantation and in Maintenance of Immune Privilege

Expression of ICOS and Foxp3 on T cells infiltrating in corneal allografts

Role of V-domain Ig suppressor of T cell activation (VISTA) in Anterior Chamber Associated Immune Deviation

Clinical statistics for recurrence of Vogt-Koyanagi-Harada disease

Long-term Ocular Analysis in Murine Model of Anterior Scleritis

Mechanisms of V-domain Ig suppressor of T cell activation (VISTA)-mediated acceptance of corneal allografts

V-domain Ig Suppressor of T Cell Activation (VISTA) is Necessary for Corneal Allograft Survival

Incidence of Endogenous Intraocular Inflammation in the Central Tokyo of Japan for 8 Years from 2004 to 2012

Induction of Corneal Inflammation in the Collagen-Induced Scleritis Model

Clinical Features and Treatment Outcome of Japanese Patients with Scleritis

To View More...

You must be signed into an individual account to use this feature.